María José
Calasanz Abinzano
Catedrática de Universidad
Hospital Universitario Reina Sofia
Córdoba, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario Reina Sofia (32)
2023
-
Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group
Blood Cancer Journal, Vol. 13, Núm. 1
-
Molecular Landscape and Validation of New Genomic Classification in 2668 Adult AML Patients: Real Life Data from the PETHEMA Registry
Cancers, Vol. 15, Núm. 2
-
Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia
British Journal of Haematology
2022
-
Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia
Cancers, Vol. 14, Núm. 11
-
Impact of FLT3–ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry Study
Cancers, Vol. 14, Núm. 23
-
The transcriptomic landscape of elderly acute myeloid leukemia identifies B7H3 and BANP as a favorable signature in high-risk patients
Frontiers in Oncology, Vol. 12
2021
-
Measurable residual disease in elderly acute myeloid leukemia: Results from the PETHEMA-FLUGAZA phase 3 clinical trial
Blood Advances, Vol. 5, Núm. 3, pp. 760-770
2016
-
Prognostic impact of chromosomal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemia patients. A study by the spanish group of myelodysplastic syndromes
Genes Chromosomes and Cancer, Vol. 55, Núm. 4, pp. 322-327
2013
-
Reciprocal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemias: Review of 5,654 patients with an evaluable karyotype
Genes Chromosomes and Cancer, Vol. 52, Núm. 8, pp. 753-763
2012
-
Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia
Leukemia, Vol. 26, Núm. 7, pp. 1517-1526
2011
-
Deregulation of FGFR1 and CDK6 oncogenic pathways in acute lymphoblastic leukaemia harbouring epigenetic modifications of the MIR9 family
British Journal of Haematology, Vol. 155, Núm. 1, pp. 73-83
-
Epigenetic activation of SOX11 in Lymphoid Neoplasms by Histone modifications
PLoS ONE, Vol. 6, Núm. 6
-
Frequent and simultaneous epigenetic inactivation of TP53 pathway genes in Acute Lymphoblastic Leukemia
PLoS ONE, Vol. 6, Núm. 2
-
LMO2 expression reflects the different stages of blast maturation and genetic features in B-cell acute lymphoblastic leukemia and predicts clinical outcome
Haematologica, Vol. 96, Núm. 7, pp. 980-986
-
Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy
Haematologica, Vol. 96, Núm. 10, pp. 1470-1477
2010
-
DNA methylation profiles and their relationship with cytogenetic status in adult acute myeloid leukemia
PLoS ONE, Vol. 5, Núm. 8
-
Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma
Blood, Vol. 116, Núm. 14, pp. 2531-2542
2009
-
A comprehensive microarray-based DNA methylation study of 367 hematological neoplasms
PLoS ONE, Vol. 4, Núm. 9
-
Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia
Cancer Research, Vol. 69, Núm. 10, pp. 4443-4453
-
MicroRNA expression profiling in Imatinib-resistant Chronic Myeloid Leukemia patients without clinically significant ABL1-mutations
Molecular Cancer, Vol. 8, pp. 69